Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2000 Mar;84(3):293-9.
doi: 10.1136/bjo.84.3.293.

Effects of topical nipradilol, a beta blocking agent with alpha blocking and nitroglycerin-like activities, on intraocular pressure and aqueous dynamics in humans

Affiliations
Clinical Trial

Effects of topical nipradilol, a beta blocking agent with alpha blocking and nitroglycerin-like activities, on intraocular pressure and aqueous dynamics in humans

M Kanno et al. Br J Ophthalmol. 2000 Mar.

Abstract

Aims: To study the effects of topical nipradilol, a non-selective beta blocker with alpha blocking and nitroglycerin-like activities, on intraocular pressure (IOP) and aqueous humour dynamics in normal humans and in patients with ocular hypertension.

Methods: Nipradilol (0.06%, 0.125%, 0.25%, 0.5%) was applied to normal volunteers (n = 12) to test for IOP lowering effects. In a second group of normal volunteers (n = 11), nipradilol (0.125% and 0.25%) and timolol (0. 5%) were compared for IOP lowering effects. After a single administration of 0.25% nipradilol, IOP, flare intensity in the anterior chamber, aqueous flow, uveoscleral outflow, tonographic outflow facility, and episcleral venous pressure were either directly measured or mathematically calculated. Topical nipradilol (0.25%) was administered to 24 patients with ocular hypertension twice daily for 8 weeks.

Results: Administration of 0.25% nipradilol decreased IOP with a maximum reduction of 4.2 mm Hg lasting 12 hours. A single instillation of both 0.25% nipradilol and 0.5% timolol reduced the IOP in normotensive human subjects to the same degree. A single instillation of 0.25% nipradilol decreased the aqueous flow rate in the treated eye by 20%. Nipradilol produced no significant effect in tonographic outflow facility or episcleral venous pressure, but uveoscleral outflow was increased. In patients with ocular hypertension, twice daily instillation of 0.25% nipradilol decreased IOP without tachyphylaxis for the 8 week test period.

Conclusion: Topical nipradilol (0.25%) reduced IOP by decreasing the aqueous flow rate and probably also by increasing uveoscleral outflow. Nipradilol should be further investigated as a new antiglaucoma drug.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Reduction in the intraocular pressure after 0.125%, 0.25% nipradilol, or 0.5% timolol instillation in drug treated eye and vehicle treated eye. Δ Intraocular pressure = difference between the change from pretreatment values in the drug treated experiment (0.125% or 0.25% nipradilol or 0.5% timolol solution instilled in one eye and vehicle in fellow eye) and that in the control experiment (vehicle solutions instilled in both eyes). Figures are significantly negative, *p<0.05. Bars represent mean (SE) (mm Hg) in 11 eyes of 11 subjects.
Figure 2
Figure 2
Intraocular pressure after twice daily instillation of 0.25% nipradilol during 8 weeks. Bars represent mean (SE) (mm Hg) in 24 eyes of 24 subjects. *Compared with week 0, v week 1; p=0.0016, v week 2; p=0.0022, v week 3; p<0.0001, v week 4; p<0.0001 (paired t test with Bonferroni's correction).

References

    1. Exp Eye Res. 1966 Jul;5(3):208-20 - PubMed
    1. Invest Ophthalmol Vis Sci. 1998 Apr;39(5):736-43 - PubMed
    1. Br J Ophthalmol. 1974 Jan;58(1):68-74 - PubMed
    1. Arch Ophthalmol. 1979 Oct;97(10):1933-6 - PubMed
    1. Arch Ophthalmol. 1980 Sep;98(9):1639-42 - PubMed

Publication types

MeSH terms